NephroGenex — Investor Presentation (December 2014)
29 slides from NephroGenex's investor presentation, Dec 11, 2014
Slide 1: Corporate Presentation December 2014
Corporate Presentation December 2014
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation includes statements that are, or may be deemed, ‘‘forward-looking statements.’’ In some cases, these forward-looking statements can be identified by the use of forward-looking terminology, including the terms “believes,” “estimates,” “anticipates,” “expec
Slide 3: Corporate Overview
Corporate Overview Late-stage company developing therapies that target the underlying cause of kidney disease Oral Pyridorin (Phase 3) – to slow progression of diabetic nephropathy (DN) - chronic I.V. Pyridorin (Preclinical) – to treat acute kidney injury (AKI) – acute Oral Pyridorin for DN is in Ph
Slide 4: The NephroGenex Team
The NephroGenex Team Member Affiliation, Position Pierre Legault, CEO Sanofi-Aventis, President Worldwide Dermatology Eckerd, President Rite Aid, CAO OSI Pharmaceuticals, CFO Prosidion Ltd, CEO Board Member, NPS, Regado Biosciences, Cyclacel, Forest Labs J. Wesley Fox, Ph.D., President & CSO BioStra
Slide 5: Financial Overview: Cash and Capital Structure
Cash As of September 30, 2014 approximately $26.6 million in cash, cash equivalents and investments $12 million term loan facility with East West Bank ($7M in November 2014 & $5M in 2015 after certain conditions are met) maturing in October 2018 Sufficient cash balance to finance operations into 201
Slide 6: The NephroGenex Pipeline
The NephroGenex Pipeline 6 Clinical Program / Indication Preclinical Phase 1 Phase 2 Phase 3 Worldwide Commercial Rights ORAL PYRIDORIN ® Diabetic Nephropathy I.V. PYRIDORIN ® Acute Kidney Injury Chronic oral bid 300 mg tablet targets pathogenic oxidative chemistries 2015 I.V. formulation for hospit
Slide 7: Pathophysiology of Diabetic Nephropathy (DN)
Pathophysiology of Diabetic Nephropathy (DN) Pyridorin targets pathogenic oxidative chemistries and AGE formation Pyridorin is an inhibitor and scavenger of these toxic carbonyls and AGEs (AGEs are recognized causative and promoting factors in DN) DN is the leading cause of dialysis and chronic kidn
Slide 8: Pyridorin Mechanism of Action
AGEs bind to receptors on the cells that comprise the glomerulus inducing pathological changes which adversely affect their filtration function. AGEs do not form and protein does not bind to receptors on the cells that comprise the glomerulus and therefore no pathology is induced. Pyridorin reacts w
Slide 9: Promising early results for Intravenous Pyridorin
Promising early results for Intravenous Pyridorin Pyridorin targets specific pathogenic oxidative chemistries that emerge in diabetes These pathogenic oxidative chemistries also emerge in hospital acquired acute kidney injury caused by: Ischemia reperfusion injury Contrast dye induced nephropathy Th
Slide 10: Ischemia-Reperfusion (I/R-AKI)
Ischemia-Reperfusion (I/R-AKI) Tubules (proximal or distal ) Tubular epithelium (damaged) Capillaries where blood is circulating Interstitial between capillaries and tubules where usually interstitial fibrosis is formed Tubular epithelium (normal) Endothelial cells Different type of blood cells 10
Slide 11: Oral Pyridorin – Significant Market Potential
Oral Pyridorin – Significant Market Potential DN patients progress from high risk, to early stage (microalbuminuria), to overt nephropathy (macroalbuminuria), to end stage renal disease (ESRD) and dialysis 19 M diagnosed diabetics in the US, of which 33% (6.3 M) exhibit kidney disease 2.8 M macroalb
Slide 12: Pyridorin well tolerated and slows rate of SCr increase
Pyridorin at a 250 mg bid dose is well tolerated and slows the rate of SCr increase in moderate to advanced disease patients Two multi-center, randomized, double-blind, placebo-controlled trials Number of centers: 20 (U.S., Belgium, United Kingdom, Canada, South Africa) Dose: 50mg BID x 2 weeks; 100
Slide 13: Phase 2b PYR-210 Established SOC patients
NephroGenex 12 Month Phase 2b PYR-210 Established SOC patients approved by FDA for Phase 3 Patients on established (or stable) standard of care (SOC) at screening exhibit a highly significant dose-dependent treatment effect in the FDA approvable RENAAL patient population Patients not on SOC at scree
Slide 14: Phase 2 Safety Trials
NephroGenex Phase 2 Safety Trials Pyridorin was well tolerated, had a benign safety profile, and slowed the rate of SCr increase in patients on stable SOC at screening No maximum dose tolerability found in animals & healthy humans There were no differences between groups in SAEs, mortality or ESRD T
Slide 15: PIONEER Pyridorin Phase 3 Trials Protocol
PIONEER Pyridorin Phase 3 Trials Protocol Objective: Evaluate safety and efficacy of Pyridorin at a 300 mg twice daily dose compared to placebo to reduce the rate of renal disease progression due to type 2 diabetes mellitus Patient Population Baseline SCr from 1.3 and less than 3.0 mg/dL (eGFR > 20
Slide 16: PIONEER Trial Interim Analysis
PIONEER Trial Interim Analysis Interim analysis expected for early 2016 The Company expects to conduct an interim analysis after all 600 patients have received at least 6 months of study drug The DSMB will be reviewing for safety The interim analysis will be event-based and conducted by an independe
Slide 17: Pyridorin Timeline
PYRIDORIN Timeline Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 17 2014 2015 2016
Slide 18: Exclusivity: Patents and New Chemical Entity
Exclusivity Patents and New Chemical Entity (NCE) No composition of matter claim since this molecule already exists in the human body in microscopic quantities U.S. Method of use (including patient population and dosage) patent December 2028 (with anticipated patent term extension) Method of manufac
Slide 19: Corporate Summary
Corporate Summary Experienced management team focused on clinical success Diabetic nephropathy represents a large and growing unmet need Oral Pyridorin Pivotal Phase 3 program in DN initiated Demonstrated benign safety profile in Phase 1 and Phase 2 a & b studies Phase 3 program is studying the pati
Slide 20: NephroGenex
p NephroGenex
Slide 21: PIONEER Pyridorin Phase 3 Trials Protocol: Endpoints
PIONEER Pyridorin Phase 3 Trials Protocol Primary end points: Evaluate Pyridorin 300 mg twice daily (BID) efficacy compared to placebo in reducing the rate of progression of renal disease due to type 2 diabetes mellitus. With time to the composite endpoint consisting of the earliest event amongst: A
Slide 22: Definition: Serum Creatinine and eGFR
Definition Serum Creatinine (SCr) – the level of creatinine, a by-product of muscle metabolism, circulating in the blood Estimated Glomerular Filtration Rate (eGFR) – an estimate of the rate that the glomerulus filters blood based on circulating SCr levels corrected for age, sex, and race Comparison
Slide 23: Pyridorin Safety Profile: PYR-210
Pyridorin Safety Profile: PYR-210 Most Reported Adverse Events Most Reported Serious Adverse Events Pyridorin has a benign safety profile with the possible exception of a small increase in diarrhea and constipation with the higher dose of 300 mg bid No meaningful differences between groups in AEs No
Slide 24: Pyridorin Phase 2a Program PYR-206
Pyridorin Phase 2a Program PYR-206 Multi-center, randomized, double-blind, placebo-controlled trial Number of centers: 46 Location of centers: U.S. Dose: 50mg BID x 24 weeks Study objectives: assess safety, tolerability and biological activity Diabetic patients with DN due to type 1 or type 2 diabet
Slide 25: Clinical Results PYR-206 Mild to Moderate DN
Clinical Results PYR-206 Mild to Moderate Diabetic Nephropathy – Dose 50 mg BID Pyridorin at a 50 mg bid dose is well tolerated and slows the rate of SCr increase in mild to moderate disease patients Note: Virtually all patients on standard of care at screening – ACEI/ARB therapy and blood pressure
Slide 26: Clinical Results PYR-205/207 Moderate to Advanced DN
Clinical Results PYR-205/207 Moderate to Advanced Diabetic Nephropathy – Dose 250 mg bid Pyridorin at a 250 mg bid dose is well tolerated and slows the rate of SCr increase in mild to moderate disease patients Note: Virtually all patients on standard of care at screening – ACEI/ARB therapy and blood
Slide 27: Clinical Results PYR-210 With and Without SOC
Clinical Results PYR-210 Type 2 Diabetic Nephropathy Patients With and Without SOC 1at screening – 300 & 150 mg bid Patients on SOC at screening exhibit a highly significant dose-dependent treatment effect in the FDA approvable RENAAL patient population Patients not on SOC at screening exhibit highe
Slide 28: NephroGenex Competitive Environment
NephroGenex Competitive Environment 28 Company Agent Phase Program Status NephroGenex Inhibitor of pathogenic oxidative chemistries and AGE formation 3 Active AbbVie Endothelin receptor antagonist 3 Active Janssen INVOKANA SGLT2 Inhibitor 3 Active Pfizer Chemokine CCR2/5 Receptor Antagonist Phosphod
Slide 29: Recent Phase 3 M&A Transactions
Date Development Stage Therapeutic Area Acquirer Acquired Transaction Market Value 7/01/2014 Phase 3 CNS Paratek Pharma Transcept Pharma $289.9 M 12/19/2014 Phase 3 Cardiovascular Jazz Pharma Gentium $860.4 M 7/30/2014 Phase 3 Infectious Diseases Cubist Pharma Optimer Pharma $674.0 M 5/28/2013 Phase